Anika Therapeutics(NASDAQ) ANIK

Market Cap$269.80M

Since IPO (1993)+476%

5 Year-50%

1 Year+144%

1 Month+27%

$21.09

+4.61%

+0.93Today

Anika Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 20.16	2026-08-06

Anika Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+11.57%	USD 18.07	2026-07-30
1 month	+27.03%	USD 15.87	2026-07-07
3 month	+36.49%	USD 14.77	2026-05-08
Year to date	+109.78%	USD 9.61	2025-12-31
1 year	+144.36%	USD 8.25	2025-08-06
3 year	-4.23%	USD 21.05	2023-08-07
5 year	-50.19%	USD 40.47	2021-08-06
Since inception	+476%	USD 3.50	1993-05-03

Anika Therapeutics Financials at a Glance

Market Cap

$269.80M

Revenue (TTM)

$120.65M

Net Income (TTM)

-$3.78M

EPS (TTM)

-$0.27

P/E Ratio

-73.58

Dividend

$0.00

Beta (Volatility)

0.83 (Low)

Dividend

$0.00

Beta (Volatility)

0.83 (Low)

Price

$21.09

Volume

77,447.388

Open

$20.60

Price

$21.09

Volume

77,447.388

Open

$20.60

Previous Close

$20.16

Daily Range

$20.09 - $21.08

52-Week Range

$7.92 - $21.12

Estimated Earnings Date

Nov 4, 2026

Dividend

$0.00

Beta (Volatility)

0.83 (Low)

Price

$21.09

Volume

77,447.388

Open

$20.60

Previous Close

$20.16

Daily Range

$20.09 - $21.08

52-Week Range

$7.92 - $21.12

Estimated Earnings Date

Nov 4, 2026

ANIK News

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Anika Therapeutics

Anika Therapeutics makes medical treatments to help people with joint pain and bone injuries. The company creates products that use a natural substance to cushion joints and help the body heal. These solutions are designed to help patients delay or avoid major surgeries.

Helping Joints Move Better

OA Pain Management: Injectable treatments like Monovisc and Cingal that reduce joint pain from wear and tear.
Regenerative Solutions: Medical scaffolds and bone fillers such as Integrity and Tactoset used to repair soft tissues and damaged bone.
Non-Orthopedic Products: Specialized medical items including wound care and eye surgery materials.
OEM Channel: Manufacturing services for large medical companies; accounted for 47% of revenue from one major customer in Q1 2026.

Refining the Business Focus

Refocused the company on pain management and regenerative solutions through a strategic shift in October 2024.
Sold Arthrosurface in October 2024 and completed the sale of Parcus Medical in March 2025.
Appointed Stephen Griffin as President and Chief Executive Officer in January 2026.
Acquired the Aristospan New Drug Application in September 2024 and sold it to a manufacturer in April 2025.

Decades of Scientific Expertise

The company leverages more than 30 years of experience in developing products using hyaluronic acid, a natural joint lubricant. It maintains a primary manufacturing hub in Bedford, Massachusetts, to supply its global network of clinical partners.

A Look at the Books

Revenue reached $29.6 million in Q1 2026, up 13.2% from $26.2 million in Q1 2025.
Gross profit was $19 million in Q1 2026, up 29.4% from $14.7 million in the prior year period.
Operating loss deepened to $5.5 million in Q1 2026, worsening 28.1% from a loss of $4.3 million in Q1 2025.
Free cash flow fell to negative $6.3 million in Q1 2026, a 112.5% deepening from negative $3 million the previous year.

Adapting for the Future

Anika has narrowed its focus by selling off surgical units to prioritize its core joint pain and tissue repair technologies. The company is currently restructuring its costs and leadership to support this more specialized business model.

AI Generated • May 15, 2026

Industry

Biotechnology

Sector

Health Care

Employees

235

CEO

Stephen D. Griffin, MBA

Website

www.anika.com

Headquarters

Bedford, MA 01730, US

ANIK Financials

Key Financial Metrics (TTM)

Gross Margin

62.16%

Operating Margin

-4.24%

Net Income Margin

-3.14%

Return on Equity

-2.70%

Return on Capital

-6.51%

Return on Assets

-2.06%

Earnings Yield

-1.36%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$269.80M

Shares Outstanding

13.38M

Volume

77.45K

Avg. Volume

80.35K

Financials (TTM)

Gross Profit

$75.00M

Operating Income

-$5.12M

EBITDA

$2.72M

Operating Cash Flow

$5.98M

Capital Expenditure

-$5.42M

Free Cash Flow

$562.00K

Cash & ST Invst.

$38.41M

Total Debt

$23.32M

Anika Therapeutics Performance Analysis

Anika Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 156,236,000	5.7%
2023	2023-12-31	USD 120,792,000	-22.7%
2024	2024-12-31	USD 119,907,000	-0.7%
2025	2025-12-31	USD 112,819,000	-5.9%

Anika Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-1.4%
Q4	2025-12-31	10.1%
Q1	2026-03-31	-3.3%
Q2	2026-06-30	10.1%

Anika Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -1.02	N/A
2023	2023-12-31	USD -5.64	452.7%
2024	2024-12-31	USD -3.83	-32.1%
2025	2025-12-31	USD -0.76	-80.2%

Anika Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	42.9%
Q4	2025-12-31	112.4%
Q1	2026-03-31	-1959.3%
Q2	2026-06-30	164.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$32.61M

+15.6%

Gross Profit

$21.24M

+47.9%

Gross Margin

65.15%

N/A

Market Cap

$269.80M

N/A

Market Cap/Employee

$1.15M

N/A

Employees

235

N/A

Net Income

$3.31M

+183.4%

EBITDA

$4.89M

+298.1%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$38.41M

-27.8%

Total Debt

$23.32M

-6.7%

Accounts Receivable

$29.06M

+21.3%

Inventory

$28.57M

+68.8%

Long Term Debt

$23.32M

+0.6%

Short Term Debt

$0.00

-100.0%

Return on Assets

-2.06%

N/A

Return on Invested Capital

-3.17%

N/A

Free Cash Flow

-$2.13M

-28.8%

Operating Cash Flow

-$684.00K

-261.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

APYXApyx Medical Corporation

APYXApyx Medical Corporation$4.05-2.64%

MXCTMaxCyte, Inc.

MXCTMaxCyte, Inc.$1.15+3.15%

ANIXAnixa Biosciences, Inc.

ANIXAnixa Biosciences, Inc.$3.43+0.00%

OWLTOwlet, Inc.

OWLTOwlet, Inc.$5.60+2.94%

LUCDLucid Diagnostics Inc.

LUCDLucid Diagnostics Inc.$0.96+0.55%

RPIDRapid Micro Biosystems, Inc.

RPIDRapid Micro Biosystems, Inc.$1.79-14.18%

LNSRLENSAR Inc

LNSRLENSAR Inc$5.97+4.10%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$128.30+0.12%

TTDThe Trade Desk

TTDThe Trade Desk$13.85-0.22%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$8.04+0.05%

NVDANvidia

NVDANvidia$221.83+0.01%

INTCIntel

INTCIntel$101.11+0.01%

DOCSDoximity

DOCSDoximity$28.52+0.38%

PLTRPalantir Technologies

PLTRPalantir Technologies$170.60+0.09%

Questions About ANIK

What is the current price of Anika Therapeutics?

Anika Therapeutics is trading at $20.94 per share.

What is the 52-week range for Anika Therapeutics?

Over the past 52 weeks, Anika Therapeutics has traded between $7.92 and $21.12.

How much debt does Anika Therapeutics have?

As of the most recent reporting period, Anika Therapeutics reported total debt of $25.25M.

How much cash does Anika Therapeutics have on hand?

Anika Therapeutics reported $38.41M in cash and cash equivalents in its most recent financial results.

What is Anika Therapeutics’s dividend yield?

Anika Therapeutics does not currently have a dividend yield.

Anika Therapeutics(NASDAQ) ANIK

Anika Therapeutics Financials at a Glance

ANIK News

Anika (ANIK) Q2 Revenue Beats by 4%

Anika Therapeutics Beats Revenue and Earnings Estimates

Why Anika Therapeutics Stock Crushed It Today

Anika Therapeutics Blows Past Q2 Earnings Estimates

Why Pivotal Software, Anika Therapeutics, and Oracle Slumped Today

Why Anika Therapeutics, Inc. Stock Is Sinking

3 Biotech Stocks to Buy in May

3 Biotech Stocks to Buy in December

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Anika Therapeutics

Helping Joints Move Better

Refining the Business Focus

Decades of Scientific Expertise

A Look at the Books

Adapting for the Future

ANIK Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Anika Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ANIK

What is the current price of Anika Therapeutics?

What is the 52-week range for Anika Therapeutics?

How much debt does Anika Therapeutics have?

How much cash does Anika Therapeutics have on hand?

What is Anika Therapeutics’s dividend yield?

Premium Investing Services